SEC Filing Summary: Flora Growth Corp. (FLGC)
Business Context and Reporting Period
This Form 8-K Current Report was filed on August 27, 2025, regarding events occurring on August 25, 2025. The registrant is Flora Growth Corp., an Ontario corporation listed on the NASDAQ Capital Market under the symbol FLGC. The filing addresses a material corporate governance event triggered by the passing of Harold Wolkin, a director of the Company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and board composition rather than financial performance.
Material Changes
- Director Departure: Harold Wolkin, an Independent Director, passed away on August 25, 2025.
- Board Composition: The Board of Directors is now comprised of four members: Sammy Dorf, Clifford Starke, Edward Woo, and Manfred Leventhal.
- Independence Status: Only two of the four remaining directors (Mr. Woo and Mr. Leventhal) qualify as Independent Directors.
- Committee Composition: The Audit Committee now consists of only two members (Mr. Woo and Mr. Leventhal), both of whom are Independent Directors.
Outlook, Risks, and Contingencies
The Company is no longer in compliance with specific NASDAQ Listing Rules due to the reduction in Independent Directors:
- Rule 5605(b)(1): Requires a majority of the Board to be Independent Directors. The current composition (2 out of 4) fails this requirement.
- Rule 5605(c)(2)(A): Requires an Audit Committee of at least three Independent Directors. The current composition (2 members) fails this requirement.
Remediation Plan: The Company is reviewing options to regain compliance within the cure period, which expires before the earlier of one year from August 25, 2026, or the next annual meeting.
Key Facts for Investor Verification
- Verify the timeline for appointing new Independent Directors to restore majority status on the Board.
- Confirm the appointment of a third Independent Director to the Audit Committee to satisfy NASDAQ Rule 5605(c)(2)(A).
- Monitor future filings for updates on the cure period status and potential listing delisting risks if compliance is not achieved.
- Note that the filing explicitly states the Company is an Emerging Growth Company.